Drug Landscape ›
Telmisartan 40mg ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 13
Most-reported reactions
Drug Dispensing Error — 2 reports (15.38%) Product Packaging Confusion — 2 reports (15.38%) Product Substitution Issue — 2 reports (15.38%) Abdominal Discomfort — 1 report (7.69%) Asthenia — 1 report (7.69%) Back Pain — 1 report (7.69%) Blood Pressure Increased — 1 report (7.69%) Covid-19 — 1 report (7.69%) Diarrhoea — 1 report (7.69%) Drug Ineffective — 1 report (7.69%)
Source database →
Telmisartan 40mg in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Telmisartan 40mg approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Telmisartan 40mg in United States?
University of Hawaii is the originator. The local marketing authorisation holder may differ — check the official source linked above.